PAM50 Finds New Purpose in the Prostate

PAM50 biomarker aids in identifying hormone therapy candidates.

Focus on Luminal A, Luminal B, Basal-like subtypes in prostate cancer.

Validated in a double-blind randomized trial.

Can utilize routine biopsies and archival specimens.

Collaboration between pathologists and clinicians is vital for success.

Next steps include further validation in various prostate cancer settings.